Enanta Pharmaceuticals, Inc. (ENTA) Stock Analysis
Healthcare · Biotechnology
Sell if holding. At $15.11, A.R:R 1.1:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Leverage penalty (D/E 1.6): -1.0; Negative news sentiment (-0.67).
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with... Read more
Sell if holding. At $15.11, A.R:R 1.1:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Leverage penalty (D/E 1.6): -1.0; Negative news sentiment (-0.67). Chart setup: No clear chart pattern; technical signals are mixed. Score 5.6/10, moderate confidence.
Passes 7/8 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 37d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: speculative.
Recent developments
updated 2026-07-05Recent Developments — Enanta Pharmaceuticals, Inc.
Latest news
- NEWS Enanta Pharmaceuticals Enters Open Market Sale Agreement With Jefferies; May Offer And Sell Up To $75M Of Common Stock T — benzinga Jul 2, 2026 neutral
Generated 2026-07-05T09:50:25Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. At $15.11, A.R:R 1.1:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Leverage penalty (D/E 1.6): -1.0; Negative news sentiment (-0.67). Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $14.05. Score 5.6/10, moderate confidence.
Take-profit target: $17.52 (+15.9% upside). Prior stop was $14.05. Stop-loss: $14.05.
Leverage penalty (D/E 1.6): -1.0; Negative news sentiment (-0.67); Elevated risk factors.
Enanta Pharmaceuticals, Inc. trades at a P/E of N/A (forward -7.7). TrendMatrix value score: 6.9/10. Verdict: Sell.
13 analysts cover ENTA with a consensus score of 4.2/5. Average price target: $20.
What does Enanta Pharmaceuticals, Inc. do?Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and...
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.